🔎 Trials Near Me

Home › Endometrial Cancer › NCT04586959

Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer

Recruiting

Who can join

Ages 18 to 90 · Women

Full eligibility criteria
Inclusion Criteria:

A subject will be considered eligible for inclusion in this study if all the following criteria are met:

1. Patient must be greater than or equal to 18 years old.
2. Suspected clinically early stage endometrial cancer of any histology (endometrioid, mixed, serous, clear-cell, carcinosarcomas, mucinous)
3. Pre-operative imaging not suggestive of extra-uterine disease, if obtained pre-operatively.
4. CA 125 testing is optional but, if obtained, must be within lab normal values. 5. ECOG performance status 0-2 (see appendix 1).

6\. Signed informed consent and ability to comply with follow-up. 7. Per the opinion of the treating investigator, the patient must be a suitable candidate for the MIS surgical procedure.

Exclusion Criteria:

A subject must not have any of the following criteria:

1. Planned laparotomic hysterectomy
2. On progesterone therapy to treat their endometrial cancer
3. Any prior pelvic irradiation

About the study

This is a prospective, multi-center, randomized non-inferiority phase III study to evaluate if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus patients who do not have a uterine manipulator placed.

What is being tested

Sponsor: Anthony Costales, MD · Participants: 278 · Started: May 21, 2021

Contact the study team

Official record on ClinicalTrials.gov — NCT04586959

Locations in the U.S.

TexasBaylor College of Medicine, Houston
Baylor College of Medicine- McNair Campus, Houston
Ben Taub General Hospital, Houston
Harris Health System - Smith Clinic, Houston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.